 |
We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.
source: Antengene Corporation Limited
【你點睇？】入場更容易？從股票每手股數到期貨合約大小，降低入場門檻會否增加你的投資意欲？► 立即投票
